Pfizer Issues RFP for 2020 Rheumatology Competitive Grant Program

Pfizer has issued an RFP for its 2020 Rheumatology Competitive Grant Program.

Through the program, grants of up to $150,000 will be awarded in support of both clinical and basic science research on the pathogenesis and treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and/or ankylosing spondylarthrosis (AS), with a focus on projects that are most relevant to improving patient care. Investigators in the United States are encouraged to apply, including young investigators in the early stages of their career.

Specific areas of interest include:

SpA — Understanding the role of JAK-STAT signaling in the pathophysiology or disease progression of spondyloarthropathies (SpA); understanding epidemiology of axSpA, including risk factors, spectrum/ progression from nr-axSpA to r-axSpA/AS; real-world evidence regarding efficacy and safety of tofacitinib in PsA as monotherapy vs. combination with csDMARDs; the efficacy and safety of tofacitinib in nr-axSpA and the long-term efficacy and safety of tofacitinib in PsA and r-axSpA; evidence for inhibition of structural progression (x-ray) and reduced inflammation (MRI, US) in r-axSpA and PsA; and response in patient subtypes (e.g., oligo/polyarticular in PsA)/dominant SpA features (e.g., peripheral SpA, uveitis, enthesitis, dactylitis, IBD).

General (RA, PsA, axSpA) — Unmet medical need/disease burden reasons for lack of/under treatment, treatment switch, patient satisfaction, and physical and psychosocial disease impact;  understanding of the efficacy and safety of tofacitinib, specifically in patients with comorbid conditions; and approaches to improving management such as treating to target by monitoring response and adjusting therapy, evidence-based treatment algorithms, and factors predictive of response to therapy.

To be eligible, the institution and principal investigator (PI) must be based in the U.S., and the PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in pharmacy, physiotherapy, or social work.

See the Pfizer website for complete program guidelines and application instructions.


Deadline: January 27, 2020